Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Michalina Marszewska"'
Autor:
Andrea Necchi, Tilman Todenhöfer, Jean-Laurent Deville, Manuel Häckl, Michalina Marszewska, Phil McKernan, Mikael Saulay, Marc Engelhardt, Maria De Santis
Publikováno v:
Journal of Clinical Oncology. 41:501-501
501 Background: DZB is an oral small-molecule FGFR1/2/3 kinase inhibitor, which showed meaningful clinical benefit in cholangiocarcinoma patients (pts) with FGFR2-driven (fusions, mutations or amplifications) tumors (NCT03230318). The current study e
Autor:
Michalina Marszewska, Stephan Braun, Anna Patrikidou, Raghad Muhsin Abdul-Karim, Mikael Saulay, Damien Pouessel, Frederique Cantero, Yohann Loriot, Arvind Chaudhry, Hyo Jin Lee, Fabricio Racca, Rodryg Ramlau, Jean-Laurent Deville, Alejandro Gonzalez
Publikováno v:
Journal of Clinical Oncology. 39:437-437
437 Background: DZB is an oral small-molecule FGFR1/2/3 kinase inhibitor, which demonstrated antitumor activity in preclinical and clinical studies (in cholangiocarcinoma patients [pts] with FGFR2-driven tumors and in FGFR1-3-driven urothelial cancer
Autor:
Arlene O. Siefker-Radtke, Joaquim Bellmunt, Frederique Cantero, Arvind Chaudhry, Michal Grzyb, Andrea Necchi, Thomas Powles, Maria De Santis, Michalina Marszewska, Paul M.J. McSheehy, Stephan Braun, Cora N. Sternberg
Publikováno v:
Journal of Clinical Oncology. 38:TPS590-TPS590
TPS590 Background: Deregulation of the FGFR signaling pathway is implicated in various cancers. In UC, FGFR genetic aberrations include FGFR1/2/3 mutations (M) and, less commonly, fusions (F), while the role of amplifications warrants further researc